Checkpoint Therapeutics (CKPT) Competitors $3.18 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$3.20 +0.02 (+0.79%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CKPT vs. ANAB, KURA, CRMD, ABUS, PHAR, IMTX, ORIC, RAPP, SEPN, and PGENShould you be buying Checkpoint Therapeutics stock or one of its competitors? The main competitors of Checkpoint Therapeutics include AnaptysBio (ANAB), Kura Oncology (KURA), CorMedix (CRMD), Arbutus Biopharma (ABUS), Pharming Group (PHAR), Immatics (IMTX), ORIC Pharmaceuticals (ORIC), Rapport Therapeutics (RAPP), Septerna (SEPN), and Precigen (PGEN). These companies are all part of the "pharmaceutical products" industry. Checkpoint Therapeutics vs. AnaptysBio Kura Oncology CorMedix Arbutus Biopharma Pharming Group Immatics ORIC Pharmaceuticals Rapport Therapeutics Septerna Precigen AnaptysBio (NASDAQ:ANAB) and Checkpoint Therapeutics (NASDAQ:CKPT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment, risk and earnings. Do analysts rate ANAB or CKPT? AnaptysBio currently has a consensus target price of $37.45, suggesting a potential upside of 93.01%. Checkpoint Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 282.90%. Given Checkpoint Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Checkpoint Therapeutics is more favorable than AnaptysBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AnaptysBio 0 Sell rating(s) 4 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.75Checkpoint Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ANAB or CKPT more profitable? Checkpoint Therapeutics has a net margin of 0.00% compared to AnaptysBio's net margin of -289.75%. Checkpoint Therapeutics' return on equity of 0.00% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets AnaptysBio-289.75% -287.94% -37.25% Checkpoint Therapeutics N/A N/A -659.07% Does the MarketBeat Community prefer ANAB or CKPT? AnaptysBio received 192 more outperform votes than Checkpoint Therapeutics when rated by MarketBeat users. However, 67.42% of users gave Checkpoint Therapeutics an outperform vote while only 66.19% of users gave AnaptysBio an outperform vote. CompanyUnderperformOutperformAnaptysBioOutperform Votes37266.19% Underperform Votes19033.81% Checkpoint TherapeuticsOutperform Votes18067.42% Underperform Votes8732.58% Do institutionals and insiders believe in ANAB or CKPT? 22.0% of Checkpoint Therapeutics shares are owned by institutional investors. 33.7% of AnaptysBio shares are owned by company insiders. Comparatively, 2.1% of Checkpoint Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has better valuation and earnings, ANAB or CKPT? Checkpoint Therapeutics has lower revenue, but higher earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Checkpoint Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnaptysBio$17.16M34.41-$163.62M-$6.08-3.19Checkpoint Therapeutics$100K1,530.33-$51.85M-$1.84-1.70 Does the media favor ANAB or CKPT? In the previous week, AnaptysBio had 12 more articles in the media than Checkpoint Therapeutics. MarketBeat recorded 12 mentions for AnaptysBio and 0 mentions for Checkpoint Therapeutics. Checkpoint Therapeutics' average media sentiment score of 0.94 beat AnaptysBio's score of 0.39 indicating that Checkpoint Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment AnaptysBio Neutral Checkpoint Therapeutics Positive SummaryCheckpoint Therapeutics beats AnaptysBio on 11 of the 18 factors compared between the two stocks. Get Checkpoint Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CKPT vs. The Competition Export to ExcelMetricCheckpoint TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$153.08M$6.99B$5.81B$9.12BDividend YieldN/A2.88%5.28%3.98%P/E Ratio-1.706.1125.7619.06Price / Sales1,530.33327.81470.1279.09Price / CashN/A75.0445.1138.24Price / Book-6.676.527.605.10Net Income-$51.85M$138.54M$3.19B$246.04M7 Day Performance-9.42%-0.57%-0.13%-0.66%1 Month Performance-1.45%1.00%3.21%0.29%1 Year Performance58.28%-2.30%19.10%15.22% Checkpoint Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CKPTCheckpoint Therapeutics3.7514 of 5 stars$3.18flat$12.00+277.4%+58.2%$155.28M$100,000.00-1.7310ANABAnaptysBio3.8751 of 5 stars$21.22+10.0%$37.45+76.5%-18.6%$645.73M$17.16M-3.49100Short Interest ↓Analyst RevisionHigh Trading VolumeKURAKura Oncology4.4262 of 5 stars$8.28flat$27.13+227.6%-59.9%$643.85MN/A-3.51130CRMDCorMedix1.2618 of 5 stars$10.48+0.4%$15.67+49.5%+237.8%$635.93M$60,000.00-12.9430Positive NewsABUSArbutus Biopharma1.8569 of 5 stars$3.29-0.3%$5.50+67.2%+16.9%$623.42M$18.14M-7.6590PHARPharming Group2.3158 of 5 stars$9.13+3.2%$27.00+195.7%-23.9%$621.19M$285.75M-35.12280Gap UpIMTXImmatics1.6655 of 5 stars$5.05-0.8%$16.67+230.0%-59.1%$602.77M$58.44M-7.65260ORICORIC Pharmaceuticals4.5798 of 5 stars$8.36+1.1%$18.71+123.9%-29.4%$589.97MN/A-4.6480Earnings ReportHigh Trading VolumeRAPPRapport Therapeutics1.7078 of 5 stars$15.90+0.8%$35.00+120.1%N/A$581.62MN/A0.00N/ASEPNSepternaN/A$12.96+12.2%$43.67+236.9%N/A$575.42MN/A0.00N/AAnalyst DowngradeNews CoveragePGENPrecigen3.9953 of 5 stars$1.96-1.0%$7.00+257.1%+43.0%$574.03M$6.22M-3.56190News Coverage Related Companies and Tools Related Companies AnaptysBio Competitors Kura Oncology Competitors CorMedix Competitors Arbutus Biopharma Competitors Pharming Group Competitors Immatics Competitors ORIC Pharmaceuticals Competitors Rapport Therapeutics Competitors Septerna Competitors Precigen Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CKPT) was last updated on 2/20/2025 by MarketBeat.com Staff From Our PartnersBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredFeb. 26 Could Send Nvidia’s “Silent Partners” SoaringNvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredBig Tech is Barreling Toward a $17 Trillion ReckoningWhile everyday investors keep piling into names like Nvidia, Apple, and Amazon... the owners of those very com...InvestorPlace | SponsoredHas Trump finally met his match?A new Chinese AI software called "DeepSeek" is sending shockwaves through the market. It's advanced enough ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Checkpoint Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Checkpoint Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CKPT Stock Alerts